| Similar Articles |
|---|
 |
BusinessWeek
October 6, 2003
Gene G. Marcial |
Dendreon: New Weapons against Tumors What's so hot about Dendreon, which leaped from 3 last year to 9.25 on Sept. 24? The little-known biotech develops immunologically based cancer remedies, and its lead product, Provenge, is aimed at prostate cancer.   |
American Family Physician
May 15, 2005 |
Early Prostate Cancer: What You Should Know A patient hand-out on the disease, who is at risk, diagnosis and treatment options. |
AskMen.com
Jen Woodward |
Prostate Cancer 101 Here are some of the basic facts about prostate cancer, along with what you can do to keep the C-word from gracing your medical chart. |
AskMen.com
Jacob Franek |
Prostate Cancer Overview Everything you wanted to know and more about prostate cancer in this three-part prostate cancer guide. |
AskMen.com
Alex Santoso |
Prostate Health 101 Most men don't have any clue about their prostate -- until things go wrong. With this information, they can maximize their prostate health. |
AskMen.com
Jacob Franek |
Prostate Cancer Symptoms, Screening & Diagnosis Despite the facts that prostate cancer is the No. 1 cancer occurring in men (aside from skin cancers) and the second leading cause of cancer death (behind lung cancer), many men are still unfamiliar with this highly treatable disease. |
BusinessWeek
February 19, 2007
Gene G. Marcial |
Will Healthy Lab Data Revive Ailing Cell Genesys? Cell genesys is in the midst of clinical trials of vaccines for prostate and pancreatic cancer that analysts believe should catch investors' eyes. |
The Motley Fool
May 4, 2009
Robert Steyer |
Beyond Provenge -- The Next Hot Cancer Drug? The search for prostate cancer treatments is filled with prospects and littered with failures. Which companies have the best chance of success? |
Science News
May 13, 2000 |
Cancer Net CancerNet is a huge compendium of information on cancer assembled by the National Cancer Institute.... |
AskMen.com
Jacob Franek |
Prostate Cancer Treatment And Prevention Everything you wanted to know about prostate cancer in our three-part Prostate Cancer Guide. |
The Motley Fool
January 12, 2004
Dave Marino-Nachison |
All Eyes on Dendreon The cancer fighter's shares rocketed today on good news out of Phase III trials. |
The Motley Fool
April 19, 2004
Charly Travers |
4 Promising Biotech IPOs Several recently gone-public biotechs boast surprisingly interesting drug pipelines. From drugs for hepatitis to hopeful cancer treatments, watch out for these four biotech debutantes. If trials go smoothly, they may be the next up-and-coming stocks in the industry. |
Chemistry World
February 11, 2009
Lewis Brindley |
Prostate Cancer Biomarker Could Speed Diagnosis US researchers have identified a compound in urine that could be used to detect prostate cancer - and also to distinguish between benign and invasive forms of the disease. |
BusinessWeek
February 6, 2006
Gene G. Marcial |
If Clinical Trials Pan Out, GTx Could Have A Winner Tiny Biotech GTx is a high-risk stock since it depends on a new drug's outcome. |
The Motley Fool
February 24, 2004
David Nierengarten |
Cell Genesys Boosted Cell Genesys's shares jump a day late and a dollar higher. |
BusinessWeek
November 3, 2003 |
Spectrum's New Cancer Weapons Several big investors have been buying little-known Spectrum Pharmaceuticals, which develops anticancer agents that have previous clinical data to back their efficacy and safety. |
Nurse Practitioner
October 2009
Wallace et al. |
Shedding light on prostate cancer This article will discuss the risk factors, signs and symptoms, diagnosis of prostate cancer, and disease staging and grading, as well as necessary lab and diagnostic tests, treatment options and patient education. |
AskMen.com
April 15, 2014
Naomi Mead |
Don't Put Your Sexual Health At Risk! Eat These 5 Foods Right Now & Protect Yourself. It is believed that a high-sugar, high-fat, processed Western diet may have a significant part to play in the increased rates of prostate cancer we are now observing. |
The Motley Fool
November 10, 2006
Brian Lawler |
Dendreon Pending Approval A lot is riding on what the FDA will say about the small pharma's drug for prostate cancer. Investors, take note. |
Chemistry World
September 2, 2014
Phillip Broadwith |
Exelexis slashes workforce by 70% The move follows poor results from a clinical trial of its cancer drug Cometriq (cabozantinib) in men with metastatic castration-resistant prostate cancer. |
The Motley Fool
June 9, 2010
Denise Gellene |
Gen-Probe Prostate Cancer Test Looks Promising The new test could eliminate need for painful biopsies. |
The Motley Fool
January 11, 2005
Charly Travers |
The Future of Cancer Vaccines Biotech companies developing cancer vaccines have been in investors' doghouses for a long time. Can a vaccine help stave off forms of the disease? |
The Motley Fool
May 10, 2005
Charly Travers |
Dendreon in the Spotlight The small biotech's prostate cancer drug is in phase 3 development. Is this company worth investing in? |
| AskMen.com |
Good Health Care News New advice from the American Cancer Society puts a sharper focus on the risks of prostate cancer screening, emphasizing that annual testing can lead to unnecessary biopsies and treatments that do more harm than good. |
The Motley Fool
May 2, 2011
Brian Orelli |
Prostate Cancer Drug Roars Ahead Johnson & Johnson's buy of Cougar paid off, but look in the rear view mirror. |
| AskMen.com |
Cholesterol & The Prostate A new study suggests that men may be able to lower their risk of getting the most aggressive form of prostate cancer by keeping their cholesterol in a healthy range. |
Chemistry World
April 17, 2008
Nuala Mora |
World's first therapeutic cancer vaccine approved In move that will be a fillip to cancer vaccine developers, US biotech Antigenics has won Russian approval to market Oncophage to treat kidney cancer. |
Salon.com
April 28, 2000
Dawn MacKeen |
A disease fueled by testosterone When a politician announces he has prostate cancer, what does it mean? |
BusinessWeek
May 23, 2005
Catherine Arnst |
If It Works for Breast Cancer... Studies are under way to see if promising strategies used against breast cancer can be used to fight other killers, such as lung, colon, and prostate cancer. |
Scientific American
November 2008
Jessica Wapner |
Cancer Vaccine: Looking Beyond Tumor Size Proponents see hope in changing cancer vaccines' bad reputation |
AskMen.com
May 27, 2002
David Dixon |
Important Information About Your Prostate Read on to learn about what men can do to protect themselves from this silent but deadly killer... |
The Motley Fool
December 23, 2011
Selena Maranjian |
3 Biotech Stocks That Had a Bad 2011 It's a volatile business, and these biotechs got the short end of the stick. |
The Motley Fool
April 26, 2004
Alyce Lomax |
Genentech's Lucky Day Genentech and OSI Pharmaceuticals jump in today's trading session after favorable trial results for a cancer drug. |
Managed Care
June 2007
Thomas Morrow |
Dendritic Cell Vaccine Hits FDA Roadblock Questions about study design and analysis prompted the FDA to postpone action on Provenge, a treatment for advanced prostate cancer. |
Fast Company
July 1, 2007 |
Going on the Gold Standard What it takes for your company to join the cancer fight. |
The Motley Fool
May 16, 2007
Brian Lawler |
GPC's Next Cancer Drug? GPC Biotech prepares for its future as it awaits an FDA decision on its lead drug. Investors, take note. |
BusinessWeek
August 26, 2010
Tom Randall |
Cocktails Are Next For Cancer-Drug Makers Taking a cue from the cocktails of drugs that have made AIDS survivable, drugmakers are pursuing combination therapies against cancer. |
ifeminists
October 15, 2002
Sacks & Thompson |
When Men's Health Doesn't Count Congress is sending a message to American men: men's health doesn't count. |
The Motley Fool
July 22, 2005
Karl Thiel |
Cancer Drug: A Shot at Success Cancer vaccine pioneer Dendreon delivered news yesterday that its investors have been anxiously awaiting: final three-year survival data from a phase 3 study of Provenge, the company's flagship prostate cancer vaccine. |
The Motley Fool
September 28, 2010
Brian Orelli |
Pfizer's Sutent Fails. Again! No surprise here. |
BusinessWeek
March 21, 2005
Gene G. Marcial |
HealthTronics, A Urologist's Best Friend Shares of little-known largest provider of urological services have been on fire, bolting from $6.32 in October to $10.40 on Mar. 9. |
The Motley Fool
September 27, 2011
Brian Orelli |
Promising Results, But It's Still Early Aeterna Zentaris' investors got a bit of good news yesterday while they wait for phase 3 data for the company's colorectal cancer drug perifosine. |
The Motley Fool
February 26, 2008
Brian Orelli |
The Less-Flashy Prostate Cancer Treatment GTx shows off clinical trial data for a drug that counters the side effects of prostate cancer treatments. |
Pharmaceutical Executive
December 1, 2010
Walter Armstrong |
Cancer: On Target Once More Over the past year or two, a handful of Phase III failures, including megablockbusters like Avastin and Sutent in trials for all kinds of common tumors, indicate that targeted therapy is generally a blunt instrument. |
Chemistry World
May 26, 2011
Mike Brown |
Ibuprofen: anticancer drug Scientists in the UK have moved a step closer to understanding how ibuprofen could help treat cancer. |
AskMen.com
March 17, 2001
Joshua Levine |
The Importance Of Regular Check-Ups For Men Men are much less likely than women to seek the routine medical care that they should. This article describes some of the risks. |
The Motley Fool
June 6, 2011
Luke Timmerman |
Exelixis Zeroes In on Lead Drug, Sees Activity in the Bones of Prostate Cancer Patients Is Exelixis' risky bet about to pay off? |
Science News
May 1, 2004
Janet Raloff |
Tea Yields Prostate Benefits Tea drinking appears to seed the body with compounds that retard the growth of prostate cancer, a new study finds. |
The Motley Fool
June 29, 2011
Brian Orelli |
4 Immunotherapies to Watch Just don't go all-in. |
Managed Care
March 2007
Martin Sipkoff |
Managing Cancer Treatment Begins Before Diagnosis Health plans are increasingly involved in promoting the lifestyle changes that help their members avoid cancer, and are increasingly involved in clinical trials if prevention fails. |
